Manufacture of pharmaceutical preparations
BJØRGVIN THERAPEUTICS GROUP AS
Revenue 2025
NOK 0
Operating profit
NOK −84,000
Equity
NOK −47,000
Incorporated
2024
Share capital
NOK 50,000
Roles
Daglig lederGro Gausdal
Styrets lederInger Reidun Fjeldskaar Aukrust
StyremedlemPer Øyvind Enger
StyremedlemJarle Sidney Diesen
StyremedlemLucia Liguori Bjørsvik
StyremedlemGro Gausdal
StyremedlemMarcel Sandberg
StyremedlemBjørn Tore Gjertsen
Shareholders
| Name | Stake | Shares | Year |
|---|---|---|---|
| TRES BIOTECHNOLOGY AS | 14.5% | 7250.000000 | 2025 |
| JARLE SIDNEY DIESEN | 14.5% | 7250.000000 | 2025 |
| EMINELL INVEST AS | 14.5% | 7250.000000 | 2025 |
| Per Øyvind Enger | 14.5% | 7250.000000 | 2025 |
| GRO GAUSDAL | 8.0% | 4000.000000 | 2025 |
| GRIFFENFELDT AS | 8.0% | 4000.000000 | 2025 |
| MARCEL SANDBERG | 8.0% | 4000.000000 | 2025 |
| CALUM LEITCH | 4.0% | 2000.000000 | 2025 |
| LUNDEVALL HOLDING AS | 4.0% | 2000.000000 | 2025 |
| ALEKSANDER DAHLE GANDRUDBAKKEN | 4.0% | 2000.000000 | 2025 |
| NICOLAS MATTIAS DEL RIO FUENZALIDA | 4.0% | 2000.000000 | 2025 |
| FRANCESCO ANGELUCCI | 2.0% | 1000.000000 | 2025 |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.